

INFORMATION DISCLOSURE CITATION

PTO-1449

 ATTY. DOCKET NO.
A-68294/DJB/RMS/DAV

 SERIAL NO.
09/404,010

 APPLICANT
LUO et al.

 FILING DATE
September 23, 1999

 GROUP
1632

U.S. PATENT DOCUMENTS

EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE

FOREIGN PATENT DOCUMENTS

EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
						Yes	No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	1	Kinnaird et al., "The isolation and characterization of genomic and cDNA clones coding for a cdc2-related kinase (ThCRK2) from the bovine protozoan parasite Theileria," <i>Mol. Microbiol.</i> , 22(2):293-302 (1996).
	2	Drewes et al., "MARK, a novel family of protein kinases that phosphorylate microtubule-associated proteins and trigger microtubule disruption," <i>Cell</i> , 89(2):297-308 (1997).
	3	Yip-Schneider et al., "Lack of elevated MAP kinase (Erk) activity in pancreatic carcinomas despite oncogenic K-ras expression," <i>Int. J. Oncol.</i> , 15(2):271-279 (1999).
	4	Birkenkamp et al., "A dual function for p38 MAP kinase in hematopoietic cells: involvement in apoptosis and cell activation," <i>Leukemia</i> , 13(7):1037-1045 (1999).
	5	Nguyen et al., "Heat shock-induced activation of stress MAP kinase is regulated by threonine- and tyrosine-specific phosphatases," <i>Genes Dev.</i> , 13(13):1653-1663 (1999).
	6	Sebolt-Leopold et al., "Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo," <i>Nat. Med.</i> , 5(7):810-816 (1999).
	7	Tomasetto et al., "TRAF-4 expression in breast carcinomas," <i>Am. J. Pathol.</i> , 153(6):2007-2008 (1998).

EXAMINER


DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

8085 1449A.FRM (8/95)

INFORMATION DISCLOSURE CITATION

PTO-1449


 ATTY. DOCKET NO.
A-68294/DJB/RMS/DAV

 SERIAL NO.
09/404,010

 APPLICANT
LUO et al.

 FILING DATE
September 23, 1999

 GROUP
1632

U.S. PATENT DOCUMENTS

EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE

FOREIGN PATENT DOCUMENTS

EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
						Yes	No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

8	Pullen et al., "CD40-tumor necrosis factor receptor-associated factor (TRAF) interactions: regulations of CD40 signaling through multiple TRAF binding sites and TRAF hetero-oligomerization," Biochemistry, 37(34):11836-11845 (1998).
9	Masson et al., "Tumor necrosis factor receptor associated factor 4 (TRAF4) expression pattern during mouse development," Mech. Dev., 71(1-2):187-191 (1998).
10	Krajewask et al., "TRAF-4 expression in epithelial progenitor cells. Analysis in normal adult, fetal, and tumor tissues," Am. J. Pathol., 152(6):1549-1561 (1998).
11	Muzio et al., "Expression of cell cycle and apoptosis-related proteins in sporadic odontogenic keratocysts and odontogenic keratocysts associated with the nevoid basal cell carcinoma syndrome," J. Dent. Res., 78(7):1345-1353.
12	Jimenez et al., "DNA-dependent protein kinase is not required for the p53-dependent response to DNA damage," Nature, 400(6739):81-83 (1999).
13	Hsieh et al., "Cell cyle effects and control of gene expression by resveratrol in human breast caricoma cell lines with different metastatic potentials," Int. J. Oncol., 15(2):245-252 (1999).
14	Pullen et al., "CD40 signaling through tumor necrosis factor receptor-associated factors (TRAFs). Binding site specificty and activation of downstream pathways by distinct TRAFs," J. Biol. Chem., 274(20):14246-14254 (1999).
15	Ishida et al., "TRAF5, a novel tumor necrosis factor receptor-associated factor family protein, mediates CD40 signaling," Proc. Natl. Acad. Sci. USA, 93((18):9437-9442 (1996).
16	Kashiwada et al., "Tumor necrosis factor receptor-associated factor 6 (TRAF6) stimulates extracellular signal-regulated kinase (ERK) activity in CD40 signaling along a ras-independent pathway," J. Exp. Med., 187(2):237-244 (1998).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
8085 1449A.FRM (8/95)